<DOC>
	<DOCNO>NCT00422604</DOCNO>
	<brief_summary>The safety , tolerability , pharmacokinetics pharmacodynamics/efficacy profile two different dos GSK233705 compare 2 active comparators placebo , medication deliver via dry powder inhaler .</brief_summary>
	<brief_title>Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>A multi-centre , randomise , partially blind , placebo-controlled , three-way crossover , incomplete block design study investigate , safety , tolerability , pharmacodynamics/efficacy pharmacokinetics dual bronchodilator therapy salmeterol 50 mcg twice daily plus two different dos GSK233705 ( 20 50 mcg twice daily ) , compare placebo , salmeterol 50 mcg twice daily alone , tiotropium 18 mcg daily alone , subject chronic obstructive pulmonary disease</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : female nonchildbearing potential postmenopausal ; history COPD define ATS/ERS criterion ; moderate COPD responsive ipratropium salbutamol ; current smoker exsmoker . Exclusion criterion : instable COPD ; max 1000 mcg inhale steroid per day ; Bblockers</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>plethysmography .</keyword>
	<keyword>muscarinic receptor antagonist</keyword>
	<keyword>anticholinergic</keyword>
</DOC>